GeNeuro announces the publication in Science Advances of data establishing clear link between human endogenous retroviral proteins and psychotic disorders

by Eclosion Team | Jul 21, 2020 | Uncategorized

Geneva, Switzerland,21July2020 –08:00amCEST –GeNeuro(Euronext Paris: CH0308403085 –GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis, today announced...

GeNeuro enrolls first patient in temelimab Phase 2 multiple sclerosis trial in collaboration with the Karolinska Institutet’s Academic Specialist Center (ASC)

by Eclosion Team | Jun 25, 2020 | Uncategorized

Geneva, Switzerland, June 25, 2020–7:30 amCEST –GeNeuro (Euronext Paris: CH0308403085 -GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseasessuch as multiple sclerosis...

NETRIS Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate NP137 in Combination with KEYTRUDA® (Pembrolizumab) in Advanced Uterine and Cervical Tumors

by Eclosion Team | May 5, 2020 | Uncategorized

NETRIS Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate NP137 in Combination with KEYTRUDA® (Pembrolizumab) in Advanced Uterine and Cervical Tumors Unique NP137 mechanism targeting netrin-1 could alleviate anti-PD-1 resistance   Lyon,...

GeNeuro appoints MS clinical development expert Dr. David Leppert as Chief Medical Officer

by Eclosion Team | Apr 21, 2020 | Uncategorized

Geneva, Switzerland, April 21, 2020–7:30am CEST –GeNeuro (Euronext Paris: CH0308403085 -GNRO), a biopharmaceutical company focused on understanding and stopping the causal factors driving the progression of neurodegenerative and autoimmune diseasessuch as multiple...

GeNeuro announces successful €17.5 million private placement

by Eclosion Team | Jan 31, 2020 | Uncategorized

Geneva, Switzerland,  January 31, 2020 – 08:00 CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases (the...

GenKyoTex reports progress of Setanaxib phase 2 investigator initiated trials

by Eclosion Team | Dec 3, 2019 | Uncategorized

Phase 2 DKD trial funded by JDRF to expand in Europe and New Zealand 13 patients have completed full 48-week treatment in DKD trial; no safety signals identified Phase 2 IPF trial funded by NIH; poised to initiate patient enrollment following recently received FDA and...